Exciting News in Schizophrenia Treatment: Teva Pharmaceuticals and Medincell Announce positive efficacy results in SOLARIS Phase 3 Trial We are thrilled to share that our latest Phase 3 trial, SOLARIS, has achieved remarkable success! TEV-749 (olanzapine), a once-monthly subcutaneous long-acting injectable, has met its primary endpoint, showing statistically significant and clinically meaningful reductions in symptom severity as measured by the Positive and Negative Syndrome Scale (PANSS). Key Highlights: Effective Results: All dose groups of TEV-749 demonstrated superior efficacy in reducing schizophrenia symptoms compared to placebo. High Tolerance: TEV-749 was well tolerated, with no cases of post-injection delirium/sedation syndrome (PDSS) observed thus far. Innovative Technology: Leveraging Medincell's proprietary Long-Acting Injectable technology, TEV-749 is designed to provide consistent medication levels with just a once-monthly injection. As our partner continues to gather additional safety data in the ongoing SOLARIS study, it remains committed to advancing this innovative treatment option For more detailed information, click to read the full story: https://lnkd.in/d9YW5Pxj
Well done Medincell !!!
Excellent piece of News ! Contrats !
Bernard Tino HUGUES 📈 suspension de cotation
Congratulations to both Medincell and Teva!
Clinical Pharmacology
5moPleased to see this and I was not aware about this partner for this development. Good choice. From both sides. Congratulations.